MESNA

Post-LOE

mesna

Sagent Pharmaceuticals

ANDAINTRAVENOUSINJECTABLE

Approved

Apr 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MESNA (mesna) by Sagent Pharmaceuticals is metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. Approved for hematuria due to other pathological conditions such. First approved in 2010.

Drug data last refreshed 18h ago

Mechanism of Action

metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic…

Indications (1)

hematuria due to other pathological conditions such

Clinical Trials (2)

NCT02235701Phase 1/2Completed

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

Started Sep 2014

70 enrolled

Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

NCT00077311Phase 2Completed

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Started Aug 2004

160 enrolled

AnemiaDrug/Agent Toxicity by Tissue/OrganLung Cancer+1 more

Worked on MESNA at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.